Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of “Hold” from Brokerages

Illumina, Inc. (NASDAQ:ILMN) has been assigned a consensus rating of “Hold” from the eighteen research firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $142.1250.

ILMN has been the topic of several research reports. Canaccord Genuity Group dropped their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Citigroup raised their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Barclays lifted their price objective on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Finally, Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a report on Thursday, May 14th.

Insider Activity at Illumina

In other news, CAO Scott D. Ericksen sold 500 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at $2,311,360. This trade represents a 3.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,003,154 shares of company stock worth $155,600,208. 2.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Illumina

A number of institutional investors have recently bought and sold shares of the stock. Elyxium Wealth LLC purchased a new position in shares of Illumina in the fourth quarter worth approximately $25,000. Board of the Pension Protection Fund purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $26,000. Creative Capital Management Investments LLC lifted its position in shares of Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in Illumina in the 4th quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC acquired a new position in Illumina in the 4th quarter worth approximately $26,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $162.47 on Thursday. The stock has a fifty day moving average price of $140.11 and a two-hundred day moving average price of $134.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The firm has a market cap of $24.58 billion, a P/E ratio of 29.54, a PEG ratio of 3.00 and a beta of 1.50. Illumina has a 1 year low of $85.77 and a 1 year high of $177.22.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts forecast that Illumina will post 5.2 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.